Strong Tower Advisory Services Boosts Holdings in Johnson & Johnson (NYSE:JNJ)

Strong Tower Advisory Services boosted its holdings in Johnson & Johnson (NYSE:JNJGet Rating) by 3.2% in the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 17,099 shares of the company’s stock after buying an additional 525 shares during the quarter. Johnson & Johnson accounts for approximately 1.6% of Strong Tower Advisory Services’ holdings, making the stock its 17th biggest position. Strong Tower Advisory Services’ holdings in Johnson & Johnson were worth $3,035,000 as of its most recent SEC filing.

Other hedge funds have also bought and sold shares of the company. RE Dickinson Investment Advisors LLC raised its position in Johnson & Johnson by 163.3% in the 1st quarter. RE Dickinson Investment Advisors LLC now owns 158 shares of the company’s stock worth $28,000 after buying an additional 98 shares during the last quarter. Advanced Research Investment Solutions LLC raised its position in Johnson & Johnson by 200.0% in the 1st quarter. Advanced Research Investment Solutions LLC now owns 180 shares of the company’s stock worth $32,000 after buying an additional 120 shares during the last quarter. Morton Brown Family Wealth LLC grew its stake in shares of Johnson & Johnson by 78.0% during the 2nd quarter. Morton Brown Family Wealth LLC now owns 178 shares of the company’s stock valued at $32,000 after purchasing an additional 78 shares during the period. Professional Financial Advisors LLC grew its stake in shares of Johnson & Johnson by 47.9% during the 1st quarter. Professional Financial Advisors LLC now owns 210 shares of the company’s stock valued at $37,000 after purchasing an additional 68 shares during the period. Finally, Goodman Advisory Group LLC bought a new stake in shares of Johnson & Johnson during the 2nd quarter valued at about $39,000. Hedge funds and other institutional investors own 68.59% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on the company. Sanford C. Bernstein cut their price target on Johnson & Johnson from $194.00 to $190.00 in a research note on Wednesday, October 19th. Citigroup cut their price target on Johnson & Johnson from $201.00 to $198.00 in a research note on Wednesday, October 5th. Atlantic Securities cut their price target on Johnson & Johnson from $165.00 to $160.00 and set a “neutral” rating for the company in a research note on Wednesday, October 19th. Credit Suisse Group started coverage on Johnson & Johnson in a research note on Thursday. They set a “neutral” rating and a $170.00 price target for the company. Finally, Barclays started coverage on Johnson & Johnson in a research note on Monday, October 17th. They set an “equal weight” rating and a $175.00 price objective for the company. Seven research analysts have rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $181.33.

Insiders Place Their Bets

In other news, EVP Kathryn E. Wengel sold 16,410 shares of the company’s stock in a transaction that occurred on Wednesday, November 9th. The stock was sold at an average price of $173.42, for a total transaction of $2,845,822.20. Following the sale, the executive vice president now directly owns 71,311 shares of the company’s stock, valued at approximately $12,366,753.62. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, EVP Kathryn E. Wengel sold 16,410 shares of the company’s stock in a transaction that occurred on Wednesday, November 9th. The stock was sold at an average price of $173.42, for a total transaction of $2,845,822.20. Following the sale, the executive vice president now directly owns 71,311 shares of the company’s stock, valued at approximately $12,366,753.62. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider William Hait sold 15,000 shares of the company’s stock in a transaction that occurred on Monday, October 24th. The stock was sold at an average price of $171.55, for a total value of $2,573,250.00. Following the sale, the insider now directly owns 80,236 shares in the company, valued at $13,764,485.80. The disclosure for this sale can be found here. Insiders sold 118,795 shares of company stock worth $20,230,174 in the last three months. 0.35% of the stock is owned by company insiders.

Johnson & Johnson Trading Up 0.8 %

JNJ stock opened at $176.20 on Friday. Johnson & Johnson has a 1-year low of $155.72 and a 1-year high of $186.69. The company has a debt-to-equity ratio of 0.37, a current ratio of 1.43 and a quick ratio of 1.18. The company has a market capitalization of $460.67 billion, a price-to-earnings ratio of 24.54, a PEG ratio of 3.47 and a beta of 0.57. The business has a 50 day simple moving average of $167.84 and a two-hundred day simple moving average of $171.35.

Johnson & Johnson (NYSE:JNJGet Rating) last posted its quarterly earnings results on Tuesday, October 18th. The company reported $2.55 earnings per share for the quarter, topping the consensus estimate of $2.49 by $0.06. Johnson & Johnson had a return on equity of 35.37% and a net margin of 19.95%. The business had revenue of $23.79 billion during the quarter, compared to the consensus estimate of $23.44 billion. During the same period in the prior year, the company posted $2.60 EPS. The firm’s revenue for the quarter was up 1.9% compared to the same quarter last year. Research analysts anticipate that Johnson & Johnson will post 10.04 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 6th. Shareholders of record on Tuesday, November 22nd will be paid a $1.13 dividend. The ex-dividend date of this dividend is Monday, November 21st. This represents a $4.52 annualized dividend and a yield of 2.57%. Johnson & Johnson’s payout ratio is 62.95%.

Johnson & Johnson announced that its Board of Directors has initiated a stock buyback program on Wednesday, September 14th that permits the company to buyback $5.00 billion in outstanding shares. This buyback authorization permits the company to purchase up to 1.2% of its shares through open market purchases. Shares buyback programs are generally a sign that the company’s board of directors believes its shares are undervalued.

About Johnson & Johnson

(Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

Read More

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJGet Rating).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.